Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Company, which has targeted new central nervous system drugs as a core therapeutic research area, entered into a $100 million research collaboration April 11 with the U.K. biotech, Heptares Therapeutics Ltd., to characterize a G-protein coupled receptor (GPCR) believed to play a role in CNS disorders